Divi's Laboratories Limited vs Manipal Health Enterprises Limited

A side-by-side comparison of Divi's Laboratories Limited (DIVISLAB) and Manipal Health Enterprises Limited (MANIPALHOS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Divi's Laboratories Limited leads DIVISLAB vs MANIPALHOS on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

85.55
P/E ratio
48.81
10.62
P/B ratio
5.22
0.36%
Dividend yield
0.00%
₹96.73
EPS
₹13.89

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
11.80%
22.00%
Return on capital
12.00%
33.00%
EBITDA margin
27.00%
24.32%
Net margin
17.24%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
63.48%
12.10%
Profit CAGR (3Y)
67.79%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.19L Cr
Market cap
₹89,104 Cr
₹10,560 Cr
Revenue
₹3,104 Cr
₹2,568 Cr
Net profit
₹535 Cr
0.00
Debt / equity
1.35
Divi's Laboratories Limited
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 13.1 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Manipal Health Enterprises Limited
  • ["Company has a low return on equity of 10.3% over last 3 years."]
Divi's Laboratories Limited full analysis Manipal Health Enterprises Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.